Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities: 2016-2025

Historic Cash from Financing Activities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $2,000.

  • Ultragenyx Pharmaceutical's Cash from Financing Activities fell 99.98% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $87.0 million, marking a year-over-year decrease of 88.03%. This contributed to the annual value of $399.2 million for FY2024, which is 2.86% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Cash from Financing Activities of $2,000 as of Q3 2025, which was down 100.00% from $83.6 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Cash from Financing Activities' 5-year high stood at $491.9 million during Q3 2022, with a 5-year trough of -$722,000 in Q1 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $11.2 million (2024), whereas its average is $79.2 million.
  • Over the last 5 years, Ultragenyx Pharmaceutical's Cash from Financing Activities had its largest YoY gain of 17,466.95% in 2023, and its largest YoY loss of 144.79% in 2023.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Cash from Financing Activities stood at $85.7 million in 2021, then slumped by 97.80% to $1.9 million in 2022, then soared by 17,466.95% to $330.6 million in 2023, then tumbled by 99.04% to $3.2 million in 2024, then crashed by 99.98% to $2,000 in 2025.
  • Its Cash from Financing Activities was $2,000 in Q3 2025, compared to $83.6 million in Q2 2025 and $157,000 in Q1 2025.